Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Inclusion Criteria

• •ELIGIBILITY CRITERIA - CASES
• •Diagnosis of primary cancer at age 21 or younger, irrespective of current age
• •No prior history of allogeneic (non-autologous) hematopoietic cell transplant
• •Development of one of the following key adverse events at any time following initiation of cancer therapy:
• •* Cardiac dysfunction; please note: case enrollment has been closed due to achievement of target accrual
• •* Ischemic stroke (IS)
• •* Subsequent malignant neoplasm (SMN)
• •* Avascular necrosis (AVN); please note: case enrollment has been closed due to achievement of target accrual
• •Submission of a blood specimen (or in certain cases a saliva specimen) to the Coordinating Center at the University of Alabama at Birmingham as per the requirements; please note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's white blood cell (WBC) is \> 2,000
• •Written informed consent from the patient and/or the patient's legally authorized guardian
• •In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; please note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required
• •ELIGIBILITY CRITERIA - CONTROLS
• •CONTROL: Diagnosis of primary cancer at age 21 or younger, irrespective of current age
• •CONTROLS: No prior history of allogeneic (non-autologous) hematopoietic cell transplant
• •CONTROLS: No clinical evidence of any of the following key adverse events:
• •* Cardiac dysfunction (CD); please note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's WBC is \> 2,000
• •* Ischemic stroke (IS)
• •* Avascular necrosis (AVN)
• •* Subsequent malignant neoplasm (SMN)
• •CONTROLS: Submission of a blood specimen (or in certain cases a saliva specimen) to the Coordinating Center Laboratory at the University of Alabama at Birmingham as per the requirements
• •CONTROLS: Written informed consent from the patient and/or the patient's legally authorized guardian
• •CONTROLS: In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; please note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required